Thrombolysis for stroke patients prescribed novel oral anticoagulants
Research type
Research Study
Full title
When to thrombolyse patients prescribed concurrent novel oral anticoagulants in acute stroke - a feasibility study
IRAS ID
160131
Contact name
Jignesh. P Patel
Contact email
Sponsor organisation
King's College London
Research summary
Current guidelines suggest that if patients suffer an acute clot-related stroke, then ideally they should be given clot-busting treatment. However, some patients are taking blood-thinning medication (anticoagulants) at the time of their stroke; this creates a problem for these patients - as giving a clot-busting medication in addition to the anticoagulant medication increases the risks of bleeding.
Over the last 10 years, a consensus has been reached, that patients taking warfarin (an anticoagulant medication) and who suffer an acute stroke can be given clot-busting medication, if their INR is <1.7 at the time of arriving at hospital. With the availability of new oral anticoagulants (apixaban, dabigatran and rivaroxaban), the question of when clot-busting treatment is safe to give to this group of patients arises once again.
This study aims to assess the anticoagulant activity of patients presenting to participating HASU centers in London with an acute stroke, prescribed all anticoagulants and describe how they are currently being managed, with the aim of testing whether a larger, England-wide study can be initiated.REC name
North West - Preston Research Ethics Committee
REC reference
14/NW/1157
Date of REC Opinion
18 Jul 2014
REC opinion
Favourable Opinion